RT Journal Article
SR Electronic
T1 Demographic characteristics of SARS-CoV-2 B.1.617.2 (Delta) variant infections in Indian population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.23.21263948
DO 10.1101/2021.09.23.21263948
A1 Kumar, Ashutosh
A1 Asghar, Adil
A1 Raza, Khursheed
A1 Narayan, Ravi K.
A1 Jha, Rakesh K.
A1 Satyam, Abhigyan
A1 Kumar, Gopichand
A1 Dwivedi, Prakhar
A1 Sahni, Chetan
A1 Kumari, Chiman
A1 Kulandhasamy, Maheswari
A1 Motwani, Rohini
A1 Kaur, Gurjot
A1 Krishna, Hare
A1 Sesham, Kishore
A1 Pandey, Sada N.
A1 Parashar, Rakesh
A1 Kant, Kamla
A1 Kumar, Sujeet
YR 2021
UL http://medrxiv.org/content/early/2021/09/26/2021.09.23.21263948.abstract
AB Importance Higher risks of contracting infection, developing severe illness and mortality are known facts in aged and male sex if exposed to the wild type SARS-CoV-2 strains (Wuhan and B.1 strains). Now, accumulating evidence suggests greater involvement of lower age and narrowing the age and sex based differences for the severity of symptoms in infections with emerging SARS-CoV-2 variants. Delta variant (B.1.617.2) is now a globally dominant SARS-CoV-2 strain, however, current evidence on demographic characteristics for this variant are limited. Recently, delta variant caused a devastating second wave of COVID-19 in India. We performed a demographic characterization of COVID-19 cases in Indian population diagnosed with SARS-CoV-2 genomic sequencing for delta variant.Objective To determine demographic characteristics of delta variant in terms of age and sex, severity of the illness and mortality rate, and post-vaccination infections.Design A cross sectional studySetting Demographic characteristics, including vaccination status (for two complete doses) and severity of the illness and mortality rate, of COVID-19 cases caused by wild type strain (B.1) and delta variant (B.1.617.2) of SARS-CoV-2 in Indian population were studied.Participants COVID-19 cases for which SARS-CoV-2 genomic sequencing was performed and complete demographic details (age, sex, and location) were available, were included.Exposures SARS-CoV-2 infection with Delta (B.1.617.2) variant and wild type (B.1) strain.Main Outcomes and Measures The patient metadata containing details for demographic and vaccination status (two complete doses) of the COVID-19 patients with confirmed delta variant and WT (B.1) infections were analyzed [total number of cases (N) =9500, Ndelta=6238, NWT=3262]. Further, severity of the illness and mortality were assessed in subsets of patients. Final data were tabulated and statistically analyzed to determine age and sex based differences in chances of getting infection and the severity of illness, and post-vaccination infections were compared between wild type and delta variant strains. Graphs were plotted to visualize the trends.Results With delta variant, in comparison to wild type (B.1) strain, higher proportion of lower age groups, particularly <20 year (0-9 year: 4.47% vs. 2.3%, 10-19 year: 9% vs. 7%) were affected. The proportion of women contracting infection were increased (41% vs. 36%). The higher proportion of total young (0-19 year, 10% vs. 4%) (p=.017) population and young (14% vs. 3%) as well as adult (20-59 year, 75% vs. 55%) women developed symptoms/hospitalized with delta variant in comparison to B.1 infection (p< .00001). The mean age of contracting infection [Delta, men=37.9 (±17.2) year, women=36.6 (±17.6) year; B.1, men=39.6 (±16.9) year and women= 40.1 (±17.4) year (p< .001)] as well as developing symptoms/hospitalization [Delta, men=39.6(± 17.4) year, women=35.6 (±16.9) year; B.1, men=47(±18) year and women= 49.5(±20.9) year (p< .001)] was considerably lower. The total mortality was about 1.8 times higher (13% vs. 7%). Risk of death increased irrespective of the sex (Odds ratio: 3.034, 95% Confidence Interval: 1.7-5.2, p<0.001), however, increased proportion of women (32% vs. 25%) were died. Further, multiple incidences of delta infections were noted following complete vaccination.Conclusions and Relevance The increased involvement of young (0-19 year) and women, lower mean age for contracting infection and symptomatic illness/hospitalization, higher mortality, and frequent incidences of post-vaccination infections with delta variant compared to wild type strain raises significant epidemiological concerns.Question Did SARS-CoV-2 B.1.617.2 (Delta) variant infections show varied demographic characteristics in comparison to wild type strains?Findings In this cross sectional study viral genomic sequences of 9500 COVID-19 patients were analyzed. As the key findings, increased involvement of young (0-19 year) and women, lower mean age for contracting infection and symptomatic illness/hospitalization, higher mortality, and frequent incidences of post-vaccination infections with delta variant in comparison to wild type (WT) strain (B.1) were observed.Meaning The findings of this study suggest that delta variant has varied demographic characteristics reflecting increased involvement of the young and women, and increased lethality in comparison to wild type strains.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:An approval from the institute ethics committee was precluded as the data used in this study were retrieved from the publicly available database Global Initiative on Sharing All Influenza Data (GISAID)(https://www.gisaid.org/).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPrimary data used for this study are publicly available on: SARS-CoV-2 genomic sequence GISAID database: https://www.gisaid.org.The tabulated data can be availed from the corresponding author on reasonable request.